Y10S 930/143
Lymphotoxin
Y10S930/143 (Lymphotoxin) appears on 14 US grants and 3 published applications in this corpus.
Search patents in Y10S- Granted patents
- 14
- Published applications
- 3
- Assignees
- 6
- Inventors
- 18
- Latest grant
- 4 Jun 2013
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 2 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 1 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
By publication year. Applications have been published since 2001.
Recent patents
- Methods for inhibiting lymphotoxin-β receptor signaling in TH1 cell-associated disorders4 Jun 2013US 8,455,445 B2Biogen Idec MA Inc.
- Soluble lymphotoxin-β receptor fusion protein and methods for inhibiting lymphotoxin β-receptor signaling31 May 2011US 7,951,371 B2Biogen Idec MA Inc.
- Methods for inhibiting lymphotoxin β receptor signalling23 Sep 2008US 7,427,403 B2Biogen Idec MA Inc.
- Soluble lymphotoxin-β receptor as a therapeutic agent for treating TH-1 cell-associated autoimmune disease30 Dec 2003US 6,669,941 B1Biogen, Inc.
- Peptide linkers for covalent linking polypeptide cell modulators8 Apr 2003US 6,545,124 B1Pharmacia Corporation
- Soluble lymphotoxin-beta receptor fusion protein and methods for inhibiting lymphotoxin beta-receptor signaling13 Oct 2011US 2011/0250200 A1Biogen Idec MA Inc.
- Soluble lymphotoxin-beta receptor fusion protein and methods for inhibiting lymphotoxin beta-receptor signaling24 Feb 2011US 2011/0046073 A1Biogen Idec MA Inc.
- Methods for inhibiting lymphotoxin beta receptor signalling17 Feb 2005US 2005/0037003 A1Biogen Idec MA Inc.
Most cited
By later US patents
- Covalently linked polypeptide cell modulators269US 4,935,233 AG. D. Searle & Co. · 1990
- Synergistic cytotoxic composition67US 4,650,674 AGenentech, Inc. · 1987
- Covalently linked polypeptide cell modulators such as interferon-lymphotoxin conjugates64US 5,114,711 AG. D. Searle & Co. · 1992
- Soluble lymphotoxin-.beta. receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease40US 5,925,351 ABiogen, Inc. · 1999
- Soluble lymphotoxin-β receptors as therapeutic agents for the treatment of immunological disease26US 6,403,087 B1Biogen, Inc. · 2002